<a href="https://www.fiercehealthcare.com/practices/breast-cancers-next-precision-medicine-revolution-may-lie-molecular-residual-disease" hreflang="en">Breast cancer’s next precision medicine revolution may lie in molecular residual disease</a>
Molecular residual disease (MRD) testing is emerging as a significant advancement in breast cancer care, particularly for triple-negative breast cancer (TNBC), by providing critical insights into treatment efficacy and recurrence risk through the analysis of circulating tumor DNA (ctDNA). This innovative approach aims to enhance personalized patient care and decision-making, potentially guiding treatment strategies and improving outcomes.
The most valuable insight for someone interested in healthtech and precision medicine is the emerging role of Molecular Residual Disease (MRD) testing in providing critical, actionable insights into treatment response and recurrence risk in breast cancer, particularly triple-negative breast cancer (TNBC). This advancement highlights a significant shift towards the integration of dynamic molecular data in oncology, potentially guiding more individualized treatment plans and improving patient outcomes. Investing in technologies and partnerships that support MRD testing could be a strategic move in the evolving precision oncology landscape.